

The subscription period in Dicot Pharma's rights issue commences today

Uppsala, Sweden, May 21, 2026. Today, the subscription period commences in Dicot Pharma AB's ("Dicot Pharma" or the "Company") rights issue of units consisting of shares and warrants of series TO 7, which was resolved by the Board of Directors on May 8, 2026 (the "Rights Issue"), in which the public also has the opportunity to subscribe for units. The subscription period runs through June 4, 2026. Please note that some nominees and banks may have an earlier deadline for subscription; therefore, shareholders are advised to check with their bank regarding the final date for subscription. The Company also invites to a live company presentation and Q&A session on May 27 at 12:00 CEST.

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.

Today, May 21, 2026, the subscription period commences in the Rights Issue, which is carried out with the primary purpose of financing the upcoming phase 2b study with the potency treatment candidate LIB-01. The subscription period runs up to and including June 4, 2026. Please note, however, that some nominees and banks may have an earlier deadline for subscribing to the Rights Issue. Subscription is made primarily through the exercise of unit rights received by existing shareholders based on their preferential rights, but shareholders and the public may also subscribe for units without unit rights. Allocation of units subscribed for without preferential rights will be made in accordance with the allocation principles set out in the EU Follow-on Prospectus published by Dicot Pharma on May 19, 2026.

By acquiring unit rights, it is possible to subscribe for more than what the preferential rights relating to the original holding entitle to, and anyone who does not intend to exercise their unit rights may sell them in the same way. Trading in unit rights, which entitle holders to subscribe for units with preferential rights, takes place during the period May 21 – June 1, 2026 and is handled by nominees and banks.

Please note that certain nominees may close the application period for exercise of unit rights prior to June 4, 2026, and may sell unit rights prior to June 1, 2026, for which the investor has not provided instructions. Investors are therefore advised to contact their nominee or bank well in advance to determine the applicable deadlines for their securities account.

Company presentation and Q&A

To answer questions regarding the Company and the Rights Issue, a company presentation and Q&A session will be held via Zoom on Wednesday, May 27 at 12:00 CEST and will also be available afterwards. Questions may be submitted in advance to info@dicotpharma.com. Registration to attend the presentation is available via https://us02web.zoom.us/webinar/register/WN_mqkLMrccTBOP9oFIQdvBA.

"The phase 2a results provided us with a strong scientific foundation and showed that LIB-01 has a profile that truly sets it apart from everything currently on the market. I am proud of what the team has achieved and delighted by the confidence we are receiving from both existing and new investors. With a fully funded phase 2b study, we are now taking the next clinical step while simultaneously building the value that creates the best possible foundation for continued partner discussions. We are in the most exciting phase in the company's history, with a clear goal of making a real difference for patients.", says Elin Trampe, CEO Dicot Pharma.

Subscription commitments and underwriting commitments

The Rights Issue is covered to approximately 80 percent by subscription commitments and underwriting commitments, corresponding to approximately SEK 168 million, in accordance with the following:

- larger existing shareholders, members of the Board of Directors and senior executives have undertaken to subscribe for Units in the Rights Issue for approximately SEK 17.7 million, corresponding to approximately 8.4 percent of the Rights Issue; and
- Schonfeld Global Master Fund LP, Anavio Capital Partners LLP and Vator Securities have provided underwriting commitments on customary terms amounting in aggregate to approximately SEK 150.5 million, corresponding to approximately 71.6 percent of the Rights Issue.

Subscription procedure

The procedure for subscribing for units in the Rights Issue depends on whether you are a nominee-registered (most common) or a directly registered shareholder. If you are uncertain which category applies to you, please contact your bank.

You hold shares through a bank or other nominee (nominee-registered shareholder)

- Contact your nominee/bank for instructions and deadlines applicable and act in accordance with such instructions. The instructions are often available when logged into your nominee's online service.
- Applications to subscribe for units without unit rights shall be made in accordance with the procedures established by the respective nominee.

You hold shares in a VP account (directly registered shareholder)

- If you exercise all unit rights, use the pre-printed bank giro payment slip distributed by Euroclear Sweden and act in accordance with the instructions provided therein. If a different number of unit rights is to be exercised than those stated on the pre-printed payment slip, the special application form distributed together with the issue statement shall be used. The application form may also be ordered from Vator Securities.

Advisers

Corpura Fondkommission AB is acting as Sole Global Coordinator and Sole Bookrunner in connection with the Issue. Advokatfirman Lindahl KB is acting as legal adviser to the Company.

Important information

The information in this press release does not constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Dicot Pharma. No action has been taken and no action will be taken to permit a public offering in any jurisdiction other than Sweden. An invitation to relevant persons to subscribe for Units in Dicot Pharma will only be made through the prospectus published by the Company.

The information in this press release may not be released, published or distributed, directly or indirectly, in or into the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa or South Korea or any other jurisdiction where such action would be unlawful, subject to legal restrictions or require measures other than those required under Swedish law. Any action in violation of this instruction may constitute a breach of applicable securities laws. This press release does not constitute an offer or invitation to acquire or subscribe for securities in the United States. No shares, subscription rights or other securities issued by the Company (the "**Securities**") have been or will be registered under the United States Securities Act of 1933 (the "**Securities Act**") or the securities legislation of any state or other jurisdiction in the United States, and no Securities may be offered, subscribed for, exercised, pledged, sold, resold, delivered or transferred, directly or indirectly, in or into the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities legislation of the relevant state or other jurisdiction in the United States. The Securities have

neither been approved nor registered, and will not be approved or registered, by the U.S. Securities and Exchange Commission, any state securities authority or any other authority in the United States. Nor has any such authority passed upon or endorsed the merits of the offering or the accuracy or reliability of the prospectus. Any representation to the contrary is a criminal offence in the United States. This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the "**Prospectus Regulation**") and has not been approved by any regulatory authority in any jurisdiction. In any EEA Member State other than Sweden, this announcement is addressed only to, and directed only at, "qualified investors" in such Member State within the meaning of the Prospectus Regulation. In the United Kingdom, this document and any other materials in relation to the securities referred to herein are being distributed and directed only at, and any investment or investment activity to which this document relates is available only to and will be engaged in only with, "qualified investors" (within the meaning of the UK version of Regulation (EU) 2017/1129, which forms part of UK law by virtue of the European Union (Withdrawal) Act 2018) who are (i) persons who have professional experience in matters relating to investments and who fall within the definition of "investment professionals" in Article 19(5) of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "**Order**"); (ii) "high net worth entities" etc. as referred to in Article 49(2)(a)-(d) of the Order; or (iii) such other persons to whom such investment or investment activity may lawfully be directed under the Order (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons. Persons who are not relevant persons should not take any action on the basis of this document and should not act or rely on it.

Forward-looking statements

This press release contains certain forward-looking information that reflects the Company's current view of future events and financial and operational development. Words such as "intends", "assesses", "expects", "may", "plans", "believes", "estimates" and other expressions that indicate or predict future developments or trends, and that are not based on historical facts, constitute forward-looking information. Forward-looking information is, by its nature, associated with both known and unknown risks and uncertainties, as it depends on future events and circumstances. Forward-looking information does not constitute any guarantee of future results or development, and actual outcomes may differ materially from those expressed in forward-looking information.

For further information, please contact:

Elin Trampe, CEO

Phone: +46 72 502 10 10

E-mail: elin.trampe@dicotpharma.com

About Dicot Pharma AB

Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma's business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market.

Dicot Pharma is listed on Nasdaq First North and has approximately 16,750 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.

This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.